Treating patients with multiple myeloma in the real world

Bookmark and Share
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 26 Jun 2020
Views: 2492
Dr Ajai Chari and Prof Roman Hájek

Dr Ajai Chari (Mount Sinai Hospital, New York City, USA) chairs a discussion with Prof Roman Hájek (University of Ostrava, Ostrava, Czech Republic) where they discuss the importance of real world data for the treatment of multiple myeloma (MM), with reference four abstracts that were presented at virtual EHA 2020 meeting.

The experts begin by discussing the role for this type of data and the differences between treating MM patients in the real world compared to clinical trials.

Dr Chari provides an overview of a study he presented at EHA 2020, which assessed recent treatment patterns, healthcare utilisation and costs in patients with in triple-class–exposed refractory disease, based in the US - which is an unmet need currently.

Prof Hájek also outlines the UVEA-IXA study, which looked at ixazomib-based treatment in relapsed/refractory MM patients who received treatment at MM specialist centres in Europe, rather than in a clinical trial setting. He states that the findings of this study are comparable to those outcomes reported in the TOURMALINE-MM1 trial.

Prof Hájek goes on to describe the HUMANS study, which looked at real world treatment patterns, healthcare resource utilisation in newly-diagnosed MM (NDMM) patients based in Denmark, Sweden and Finland. He notes that the findings of this trial reinforce current clinical guidelines, where bortezomib- based treatment is commonly used to treat NDMM patients (who have not been treated with ASCT) in the first-line setting. Dr Chari also gives his perspective on this confirmatory analyses and notes the importance of global practice patterns in this regard.

The experts conclude the session by discussing the management of frail MM patients in the real world, with Dr Chari giving an overview of a further study presented at the meeting, which examined the frail MM population in Spain, using various methods to assess frailty and co-morbidity, as used in the INSIGHT MM study.

Dr Chari and Prof Hájek emphasise that this patient population is significantly under-represented in clinical trials currently, and more effort is urgently needed to increase our understanding of how to best care for this specific subgroup - as MM is known to typically affect the elderly population.

This programme has been supported by an unrestricted educational grant from Takeda.